Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Completed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

Key facts

Study ID: NCT00454870
Run by: Memory Pharmaceuticals
People needed: 80
Starts: 2007-02-01
Expected to finish: 2007-10-01
Last updated by the study team: 2008-05-06

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of probable or possible Alzheimer's disease
MMSE score between 16 and 26 points
Modified Hachinski Ischemia Score of less than or equal to 4
Capable of performing cognitive tests and other procedures specified in protocol

You may not qualify if…

Head trauma associated with cognitive impairment
Evidence of significant neurological disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, CNS tumor, progressive supranuclear palsy, seizure disorder, etc.
Received AChE inhibitor therapy (e.g., rivastigmine, tacrine or galantamine) or NDMA-receptor antagonist, memantine, within 30 days or donepezil within 40 days of randomization
Received any investigational drug within 2 months of randomization or treatment with other nicotinic receptor agonists within 3 months of screening

Where it is running

Study site — Phoenix, Arizona, United States
Study site — Glendale, California, United States
Study site — Atlanta, Georgia, United States
Study site — Wichita, Kansas, United States
Study site — Wichita, Kansas, United States
Study site — Willingboro, New Jersey, United States
Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.